404 related articles for article (PubMed ID: 28251513)
21. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
Choby B
FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
[TBL] [Abstract][Full Text] [Related]
22. Adverse Effects Associated With Newer Diabetes Therapies.
Akiyode OF; Adesoye AA
J Pharm Pract; 2017 Apr; 30(2):238-244. PubMed ID: 26169212
[TBL] [Abstract][Full Text] [Related]
23. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
24. An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective.
Saisho Y
Expert Opin Pharmacother; 2020 Sep; 21(13):1565-1578. PubMed ID: 32521177
[TBL] [Abstract][Full Text] [Related]
25. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
26. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
Egger A; Kraenzlin ME; Meier C
Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular effects of antidiabetic drugs.
Sørensen AM; Christensen MB
Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
[TBL] [Abstract][Full Text] [Related]
29. New Agents for the Treatment of Type 2 Diabetes.
Libianto R; Ekinci EI
Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
[TBL] [Abstract][Full Text] [Related]
30. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
31. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
32. Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.
Payk SL; Drew RH; Smith JD; Jiroutek MR; Holland MA
Clin Ther; 2015 Jul; 37(7):1477-1482.e1. PubMed ID: 26024569
[TBL] [Abstract][Full Text] [Related]
33. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
[TBL] [Abstract][Full Text] [Related]
34. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
[TBL] [Abstract][Full Text] [Related]
36. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
[TBL] [Abstract][Full Text] [Related]
37. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
38. Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people.
Emmerton D; Abdelhafiz A
Hosp Pract (1995); 2021 Aug; 49(3):164-175. PubMed ID: 33729898
[TBL] [Abstract][Full Text] [Related]
39. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
40. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]